-+ 0.00%
-+ 0.00%
-+ 0.00%

Opthea Taps Daniel Geffken Of Danforth Advisors As Interim CFO, Effective September 9, Taking Over From Peter Lang

Benzinga·09/05/2024 10:06:41
Listen to the news

Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))))), a clinical-stage biopharmaceutical Company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced executive leadership changes in Commercial and Finance as well as senior hires for Biometrics, Clinical Operations and Market Access.

The following organizational changes further deepen the Company's expertise in retina, expand its clinical capabilities, while advancing Opthea's commercial readiness, in anticipation of the Phase 3 topline data readout of sozinibercept in wet AMD in 2025:

Daniel Geffken, Co-Founder and Managing Director, Danforth Advisors, will assume the role of Chief Financial Officer on an ad interim basis reporting to Frederic Guerard, PharmD, Chief Executive Officer, Opthea, effective September 9, 2024. Mr. Geffken is a proven leader of finance organizations in life science companies with more than 30 years of experience steering strategy, finance, and operations across all stages of the corporate life cycle. He has served as CFO, strategic consultant and board member to dozens of life science companies ranging from start-ups to publicly traded companies with US$2+ billion market capitalizations.

Daniel Geffken succeeds Peter Lang who decided to leave the Company for personal reasons effective September 9, 2024. During his tenure, he participated in the most recent round of financing which successfully raised US$150 million, significantly extending the Company's cash runway.